Actions of Modern (NASDAQ:MRNA) jumped more than 14% on Friday, following reports of a major new cancer research initiative.
Image source: Getty Images.
Did you miss Nvidia in 2009? This rare signal flashes again. In 2009, a “Double Down” signal sounded for a little-known chipmaker called Nvidia. For the first time in years, this same signal of “total conviction” rings out for a company a hundredth the size of Nvidia. Continue “
A new counter-offensive against cancer
The National Institutes of Health (NIH) plans to launch a campaign to accelerate cancer treatment research in December, according to a report from the The New York Times. The program hopes to replicate the success of efforts to develop Covid-19 vaccines during the early stages of the pandemic.
The public-private partnership would bring together researchers and other resources from a range of health care companies and nonprofit organizations to accelerate scientific discoveries. Initial research should focus on pancreatic, liver and colorectal cancers, as well as pediatric tumors.
Moderna is a leader in cancer vaccine research
This initiative comes at a time when advances in artificial intelligence (AI) and mRNA technology are allowing doctors to design treatments tailored to each patient’s immune system.
On August 19, Moderna and Merck (NYSE: MRK) announced that its investigational mRNA-based treatment, intismeran, which it co-developed, when administered in combination with Merck’s Keytruda, increased the time before cancer returns or spread in high-risk melanoma patients.
These findings, along with other encouraging clinical trial results, are prompting health care leaders to devote more resources to cancer research. This could help accelerate Moderna’s development timelines, potentially allowing the biotech to deliver new therapies to patients – and profits to shareholders – faster than expected.
Should you buy Moderna stock right now?
Before buying Moderna stock, consider this:
The motley fool Equity Advisor The analyst team has just identified what they think is the 10 best stocks for investors to buy now…and Moderna wasn’t one of them. The 10 selected stocks are designed for long-term growth and could produce monster returns in the years to come.
Consider when Netflix made this list on December 17, 2004…if you had invested $1,000 at the time of our recommendation, you would have $385,972!* Or when Nvidia made this list on April 15, 2005…if you had invested $1,000 at the time of our recommendation, you would have $1,416,196!*
Gn bussni
